Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy

International Journal of Infectious Diseases

Volumn 12, Issue 6, 2008, Pages

  Nuttall, James J ^a   Davies, Mary Ann ^a,b   Hussey, Gregory D ^a,c   Eley, Brian S ^a  

^a RED CROSS WAR MEMORIAL CHILDREN S HOSPITAL   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Adverse events; Bacillus Calmette Gu rin; Highly active antiretroviral therapy; HIV 1

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BCG VACCINE; EFAVIRENZ; ETHIONAMIDE; ISONIAZID; LAMIVUDINE; NEVIRAPINE; OFLOXACIN; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ABSCESS; ABSCESS DRAINAGE; ARTICLE; AXILLARY LYMPHADENITIS; BACTERIUM ISOLATION; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; DEMOGRAPHY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INJECTION SITE ULCER; LUNG TUBERCULOSIS; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM BOVIS; PRESCHOOL CHILD; PREVALENCE; RISK FACTOR; SIDE EFFECT; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BCG VACCINE; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MYCOBACTERIUM BOVIS; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 54349120210     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.06.014     Document Type: Article

References (22)

1. Dorrington R, Johnson L, Bradshaw D, Daniel TJ. The demographic impact of HIV/AIDS in South Africa: national and provincial indicators for 2006. South Africa: Centre for Actuarial Research, South African Medical Research Council and the Actuarial Society of South Africa; 2006. Available at: http://www.mrc.ac.za/bod/DemographicImpactHIVIndicators.pdf (accessed August 2008).
2. Meyers T., Moultrie H., Naidoo K., Cotton M., Eley B., and Sherman G. Challenges to pediatric HIV care and treatment in South Africa. J Infect Dis 196 Suppl 3 (2007) S474-S481
3. Mohamed H., Kibel M., Hawkridge T., Schaaf H.S., Hanekom W.A., Iloni K., et al. The impact of a change in Bacille Calmette-Guerin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa. Pediatr Infect Dis J 25 (2006) 1167-1172
4. World Health Organization. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 82 (2007) 193-196
5. Lotte A., Wasz-Hockert O., Poisson N., Engbaek H., Landmann H., Quast U., et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 63 (1988) 47-59
6. Talbot E.A., Perkins M.D., Silva S.F., and Frothingham R. Disseminated Bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 24 (1997) 1139-1146
7. Jeena P.M., Chhagan M.K., Topley J., and Coovadia H.M. Safety of the intradermal Copenhagen 1331 BCG vaccine in neonates in Durban, South Africa. Bull World Health Organ 79 (2001) 337-343
8. Hesseling A.C., Rabie H., Marais B.J., Manders M., Lips M., Schaaf H.S., et al. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 14 (2006) 548-558
9. Fallo A., Torrado L., Sanches A., Cerqueiro C., Schagrodsky L., and Lopez E.L. Delayed complications of Bacille Calmette-Guerin (BCG) vaccination in HIV-infected children 2005. Proceedings of the 3rd IAS conference on HIV pathogenesis and treatment, July 24-27, 2005 (2005), International AIDS Society, Rio de Janeiro, Brazil
10. Hesseling A.C., Marais B.J., Gie R.P., Schaaf H.S., Fine P.E.M., Godfrey-Faussett P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25 (2007) 14-18
11. Sharp M.J., and Mallon D.F. Regional bacillus Calmette-Guérin lymphadenitis after initiating antiretroviral therapy in an infant with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 17 (1998) 660-662
12. Puthanakit T., Oberdorfer P., Punjaisee S., Wannarit P., Sirisanthana T., and Sirisanthana V. Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 41 (2005) 1049-1052
13. Kroidl A., Huck K., Weinspach S., Gudowius S., Mackenzie C.R., Oette M., et al. Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette-Guerin (BCG) in an HIV-positive child. Scand J Infect Dis 38 (2006) 716-718
14. Alexander A., and Rode H. Adverse reactions to the bacillus Calmette-Guerin vaccine in HIV-positive infants. J Pediatr Surg 42 (2007) 549-552
15. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. 2003 revision. Available at: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf. (accessed August 2008).
16. Hesseling A.C., Schaaf H.S., Hanekom W.A., Beyers N., Gie R.P., Marais B.J., et al. Danish Bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 37 (2003) 1226-1233
17. Roditi D, Lambrick M, Nicol M, Chojnack M, Eley B, Steyn L. The use of PCR to distinguish clinical isolates of BCG from Mycobacterium bovis. Abstract. Presented at the Joint Congress of the Infectious Diseases and Sexually Transmitted Diseases Societies of Southern Africa, December 2001, Stellenbosch, South Africa.
18. Glencross D., Scott L.E., Jani I.V., Barnett D., and Janossy G. CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell enumeration. Cytometry 15 (2002) 69-77
19. Shankar E.M., Vignesh R., Murugavel K.G., Balakrishnan P., Sekar R., Lloyd C.A., et al. Immune reconstitution inflammatory syndrome in association with HIV/AIDS and tuberculosis: views over hidden possibilities. AIDS Res Ther 4 (2007) 29
20. Kampmann B., Tena-Coki G.N., Levin M., and Eley B.S. Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS 20 (2006) 1011-1018
21. Grange J.M. Complications of bacille Calmette-Guérin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health 1 (1998) 84-88
22. Nicol M., Eley B., Kibel M., and Hussey G. Intradermal BCG vaccination-adverse reactions and their management. S Afr Med J 92 (2002) 39-42